Medpace Holdings, Inc. (MEDP) Debt Components
- 2023-12-31: Short-term DebtUSD $0.00; Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Line of CreditUSD (m).
- 2023-09-30: Short-term DebtUSD $0.00; Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Line of CreditUSD (m).
- 2023-06-30: Short-term DebtUSD $55.00M; Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Line of CreditUSD (m).
- 2023-03-31: Short-term DebtUSD $115.00M; Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Line of CreditUSD (m).
Medpace Holdings, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Short-term Debt USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Line of Credit USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Interest Rate at Period End pure | Long-term Debt, Gross USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $55.00M | (m) | (m) | (m) | (m) | $55.00M | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $115.00M | (m) | (m) | (m) | (m) | $115.00M | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $50.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $50.00M | (m) | $50.00M | (m) | (m) | (m) | (m) | (m) | (m) | 5.30% | (m) | (m) | (m) |
| 2022-09-30 | $139.70M | (m) | (m) | $139.70M | (m) | $139.70M | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $249.70M | (m) | (m) | $249.70M | (m) | $249.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-15 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $250.00M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2019-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2019-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2019-03-31 | (m) | (m) | $55.78M | (m) | (m) | (m) | $0.00 | $56.44M | (m) | (m) | $0.00 | (m) | (m) | $56.44M | (m) | $258.00K |
| 2018-12-31 | (m) | (m) | $79.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $282.00K |
| 2018-12-31 | (m) | $0.00 | (m) | (m) | (m) | $0.00 | $0.00 | $80.44M | (m) | (m) | (m) | (m) | (m) | $80.44M | (m) | (m) |
| 2018-09-30 | (m) | $0.00 | $113.69M | (m) | (m) | (m) | $0.00 | $15.47M | $99.00M | (m) | $0.00 | (m) | (m) | $114.47M | (m) | $307.00K |
| 2018-06-30 | (m) | $16.50M | $147.02M | (m) | (m) | (m) | $16.50M | $20.62M | $119.00M | (m) | $8.25M | (m) | (m) | $164.38M | (m) | $336.00K |
| 2018-03-31 | (m) | $16.50M | $181.07M | (m) | (m) | (m) | $16.50M | $20.62M | $149.00M | (m) | $12.38M | (m) | (m) | $198.50M | (m) | $367.00K |
| 2017-12-31 | (m) | $16.50M | $205.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $399.00K |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $16.50M | $16.50M | $20.62M | $169.00M | (m) | (m) | (m) | (m) | $222.62M | (m) | (m) |
| 2017-09-30 | (m) | $15.47M | $169.15M | (m) | (m) | (m) | $16.50M | $16.50M | $20.62M | $129.00M | $3.09M | (m) | (m) | $185.72M | (m) | $432.00K |
| 2017-06-30 | (m) | $14.44M | $143.19M | (m) | (m) | (m) | $16.50M | $16.50M | $20.62M | $99.00M | $6.19M | (m) | (m) | $158.81M | (m) | $466.00K |
| 2017-03-31 | (m) | $13.41M | $147.23M | (m) | $161.91M | (m) | $16.50M | $16.50M | $20.62M | $99.00M | $9.28M | (m) | (m) | (m) | (m) | $500.00K |
| 2016-12-31 | (m) | $12.38M | $151.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $534.00K |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $165.00M | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | $165.00M | $12.38M | $16.50M | $16.50M | $20.62M | $99.00M | (m) | (m) | (m) | (m) | 4.90% | (m) |
| 2016-09-30 | (m) | $6.00K | $154.61M | (m) | $165.01M | (m) | $0.00 | $0.00 | $0.00 | (m) | $6.00K | (m) | (m) | $165.01M | (m) | $1.70M |
| 2015-12-31 | (m) | $59.00K | $377.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $390.06M | (m) | $1.98M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |